Crossmark

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Crossref DOI link: https://doi.org/10.1007/s00415-021-10599-2

Published Online: 2021-05-22

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Graf, Tilmann

Thiele, Thomas

Klingebiel, Randolf

Greinacher, Andreas

Schäbitz, Wolf-Rüdiger

Greeve, Isabell https://orcid.org/0000-0002-0534-297X
Funding

Funding for this research was provided by:

v. Bodelschwinghsche Stiftungen Bethel
License Information

Text and Data Mining valid from 2021-05-22

Version of Record valid from 2021-05-22
More Information

Article History

Received: 28 April 2021

Revised: 3 May 2021

Accepted: 4 May 2021

First Online: 22 May 2021

Declarations

:

: All procedures performed in the case report were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: The authors declare that they have no conflict of interest.

: Patient signed informed consent regarding publishing his data and CT/MRI scans.

Document is current

Any future updates will be listed below